# PRODUCT INFORMATION

## YCH1899

*Item No. 39737*

| | |
|---|---|
| **Formal Name:** | 4-(3-(3-(5-bromofuran-2-yl)-5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazine-7-carbonyl)-4-fluorobenzyl)phthalazin-1(2H)-one |
| **MF:** | $C_{25}H_{18}BrFN_6O_3$ |
| **FW:** | 549.4 |
| **Purity:** | ≥98% |
| **Supplied as:** | A solid |
| **Storage:** | -20°C |
| **Stability:** | ≥3 years |




*Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.*

### Laboratory Procedures

YCH1899 is supplied as a solid. A stock solution may be made by dissolving the YCH1899 in the solvent of choice, which should be purged with an inert gas. YCH1899 is soluble in DMSO.

### Description

YCH1899 is an inhibitor of poly(ADP-ribose) polymerase 1 (PARP1) and PARP2 ($IC_{50}$s = <0.001 nM for both).[1] It is selective for PARP1 and PARP2 over PARP3, -4, -5A, -5B, -6, -7, -10, and -12 ($IC_{50}$s = 1-14.1 nM). YCH1899 inhibits the proliferation of Capan-1 cells ($IC_{50}$ = 0.1 nM), as well as Capan-1 cells resistant to the PARP inhibitors talazoparib (BMN 673; Item No. 19782) or olaparib (Item No. 10621; $IC_{50}$s = 1.13 and 0.89 nM, respectively). It inhibits the proliferation of *BRCA1* mutant HCC1937 breast cancer cells ($IC_{50}$ = 4.54 nM). *In vivo*, YCH1899 (12.5 and 25 mg/kg) reduces tumor growth in an olaparib-resistant MDA-MB-436 breast cancer mouse xenograft model.

### Reference


1. Sun, Y., Yang, H., Yuan, J., *et al.* YCH1899, a highly effective phthalazin-1(2*H*)-one derivative that overcomes resistance to prior PARP inhibitors. *J. Med. Chem.* **66(17),** 12284-12303 (2023).





**CAYMAN CHEMICAL**
1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA
**PHONE:** [800] 364-9897
[734] 971-3335
**FAX:** [734] 971-3640
CUSTSERV@CAYMANCHEM.COM
WWW.**CAYMANCHEM**.COM